Press releases
- Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
- Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
- Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
- Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
More ▼
Key statistics
On Friday, Arrowhead Pharmaceuticals Inc (HDP1:BRN) closed at 36.56, 0.00% below its 52-week high of 36.56, set on May 05, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 36.56 |
---|---|
High | 36.56 |
Low | 36.56 |
Bid | 37.09 |
Offer | 37.30 |
Previous close | 36.56 |
Average volume | -- |
---|---|
Shares outstanding | 123.90m |
Free float | 118.33m |
P/E (TTM) | -- |
Market cap | 2.80bn USD |
EPS (TTM) | -2.77 USD |
Data delayed at least 15 minutes, as of May 05 2023.
More ▼